Company profile: Telo Genomics
1.1 - Company Overview
Company description
- Provider of telomere-based platforms for biopsies and related technologies in oncology and neurological diseases. Offerings include TeloView, which quantifies genomic instability by measuring the 3D structure and spatial organization of telomeres to assess disease aggressiveness and treatment response, and TeloView SMM, a molecular assay identifying high-risk Smouldering Multiple Myeloma patients for treatment intervention decisions.
Products and services
- Telomere Platform for Biopsies: Supports telomere-based technologies on biopsy specimens across oncology and neurological diseases for telomere analysis and applications, biopsy-focused
- TeloView: Quantifies genomic instability by measuring 3D telomere structure and spatial organization to assess disease aggressiveness and treatment response, quantitative
- TeloView SMM: Identifies high-risk Smouldering Multiple Myeloma patients using telomere-based molecular analysis to inform treatment intervention decisions, assay-based
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Telo Genomics
JEOL
HQ: United States
Website
- Description: Provider of SEM and TEM (including cryo-EM) for high-resolution imaging and analysis, mass spectrometers for protein characterization, pharmaceuticals and high-throughput screening, NMR spectrometers for molecular structure analysis, EPMA for elemental analysis and high spatial resolution imaging, and FIB systems for sample preparation, imaging and analysis; based in Peabody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JEOL company profile →
Abraxis BioScience
HQ: United States
Website
- Description: Provider of next-generation therapeutics and core technologies for the treatment of cancer and other critical illnesses; engages in the discovery, development, and delivery of therapies, including Abraxane, a nanoparticle chemotherapeutic compound.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abraxis BioScience company profile →
Ionpath
HQ: United States
Website
- Description: Provider of ion beam–based multiplexed tissue imaging and spatial proteomics solutions, including the MIBIscope system with instrumentation, validated reagents, and visualization software; MIBI technology imaging 40+ protein markers per scan; MIBIplus single-cell analysis detecting 50+ phenotypes; Spatial Proteomic Services for segmentation, classification, and spatial analysis; and conjugated antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ionpath company profile →
Cord:Use
HQ: United States
Website
- Description: Provider of cord blood and tissue banking services, preserving umbilical cord stem cells used in treating nearly 80 diseases, and public cord blood donation to build an inventory for patients needing transplants. Offers planned infusion clinics administering cellular therapies under FDA-approved INDs, conducts R&D on treatments for autism and cerebral palsy, and delivers virtual educational seminars.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cord:Use company profile →
Reveal Biosciences
HQ: United States
Website
- Description: Provider of computational pathology diagnostics using AI to analyze large whole slide microscope images, combining a histopathology laboratory with machine learning to diagnose disease. Offers a new class of diagnostics with fundamental improvements in reach, cost, speed, accuracy, and scale in disease diagnosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reveal Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Telo Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Telo Genomics
2.2 - Growth funds investing in similar companies to Telo Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Telo Genomics
4.2 - Public trading comparable groups for Telo Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →